WICHITA, Kan. (KWCH) - Kansas children battling leukemia have a new hope for survival thanks to a new treatment available in Wichita. KU School of Medicine-Wichita Doctors Nathan Hall and Brian Pate ...

In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

In this video, Marlise R. Luskin, MD, MSCE, discusses results from a phase 3 randomized trial that investigated the addition of blinatumomab to standard chemotherapy for pediatric B-cell acute ...

Nicole worked as an oncology nurse at the Alberta Children’s Hospital. It was impossible to believe that one of her children ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

KU School of Medicine-Wichita Department of Pediatrics and Wesley Children’s Hospital say a groundbreaking treatment for ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Amgen’s Blincyto (blinatumomab) has been approved by the European Commission (EC) to treat certain acute lymphoblastic ...

The European Commission (EC) has approved Blincyto (blinatumomab) monotherapy as part of consolidation therapy for the treatment of adults with newly-diagnosed Philadelphia chromosome-negative ...

An initial round of chemotherapy affected her digestive system so doctors are now considering Blinatumomab — an immunotherapy treatment for ALL that Ms Douglas said is estimated to cost $120,000 ...

MP0533 also binds CD3, which is expressed on cytotoxic T-cells and is the principle mechanism of action of approved T-cell engagers like blinatumomab, tarlatamab, epcoritamab, and others.